Kamada, which is focused on orphan drugs and plasma-derived protein therapeutics, announced terms for its IPO on Wednesday. The Ness Ziona, Israel-based company plans to raise $60 million by offering 5.6 million shares at a price of $10.75. At the proposed price, Kamada would command a market value of $369 million. The company currently trades on the Tel Aviv Stock Exchange under the ticker KMDA.
Kamada, which was founded in 1990 and booked $66 million in sales for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on January 24, 2013. Morgan Stanley and Jefferies & Co. are the joint bookrunners on the deal.
